Literature DB >> 7617680

Maternal naltrexone prevents morphological and behavioral alterations induced in rats by prenatal stress.

G I Keshet1, M Weinstock.   

Abstract

The influence of opioid receptor blockade on the developmental and behavioral effects of prenatal stress was studied. Time-mated dams were implanted with minipumps on day 17 of gestation containing vehicle (V) or naltrexone (NTX, 10 mg/kg/day). Noise and light stress was applied on an unpredictable basis, three times a week throughout gestation to half the dams. Maternal NTX completely prevented the reduction in anogenital distance in prenatally stressed (PS) males and restored the growth rate of both sexes. NTX also decreased the anxiety of PS rats in the plus-maze, increased the opioid component of exploration to control levels, but increased anxiety in control males. NTX did not restore the lower saccharin preference in PS females and decreased it in C females. This suggests that some morphological and behavioral changes induced by prenatal stress could result from excess opioid activity induced by maternal stress.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7617680     DOI: 10.1016/0091-3057(94)00289-u

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  12 in total

1.  Developmental exposure to corticosterone: behavioral changes and differential effects on leukemia inhibitory factor (LIF) and corticotropin-releasing hormone (CRH) gene expression in the mouse.

Authors:  Robert N Pechnick; Anastasia Kariagina; Evelyn Hartvig; Catherine J Bresee; Russell E Poland; Vera M Chesnokova
Journal:  Psychopharmacology (Berl)       Date:  2006-01-14       Impact factor: 4.530

Review 2.  A risk-benefit assessment of naltrexone in the treatment of alcohol dependence.

Authors:  B J Berg; H M Pettinati; J R Volpicelli
Journal:  Drug Saf       Date:  1996-10       Impact factor: 5.606

Review 3.  The transgenerational transmission of childhood adversity: behavioral, cellular, and epigenetic correlates.

Authors:  Nicole Gröger; Emmanuel Matas; Tomasz Gos; Alexandra Lesse; Gerd Poeggel; Katharina Braun; Jörg Bock
Journal:  J Neural Transm (Vienna)       Date:  2016-05-12       Impact factor: 3.575

4.  A Retrospective Cohort Study of Birth Outcomes in Neonates Exposed to Naltrexone in Utero: A Comparison with Methadone-, Buprenorphine- and Non-opioid-Exposed Neonates.

Authors:  Erin Kelty; Gary Hulse
Journal:  Drugs       Date:  2017-07       Impact factor: 9.546

Review 5.  Gender differences in the effects of prenatal stress on brain development and behaviour.

Authors:  Marta Weinstock
Journal:  Neurochem Res       Date:  2007-04-04       Impact factor: 3.996

6.  Prenatal exposure to stressful life events is associated with masculinized anogenital distance (AGD) in female infants.

Authors:  Emily S Barrett; Lauren E Parlett; Sheela Sathyanarayana; Fan Liu; J Bruce Redmon; Christina Wang; Shanna H Swan
Journal:  Physiol Behav       Date:  2013-03-13

7.  Sex-dependent programming effects of prenatal glucocorticoid treatment on the developing serotonin system and stress-related behaviors in adulthood.

Authors:  R Hiroi; D L Carbone; D G Zuloaga; H A Bimonte-Nelson; R J Handa
Journal:  Neuroscience       Date:  2016-02-02       Impact factor: 3.590

8.  Prenatal stress alters cardiovascular responses in adult rats.

Authors:  N Igosheva; O Klimova; T Anishchenko; V Glover
Journal:  J Physiol       Date:  2004-03-19       Impact factor: 5.182

9.  Prenatal Stress Alters Progestogens to Mediate Susceptibility to Sex-Typical, Stress-Sensitive Disorders, such as Drug Abuse: A Review.

Authors:  Cheryl A Frye; Jason J Paris; Danielle M Osborne; Joannalee C Campbell; Tod E Kippin
Journal:  Front Psychiatry       Date:  2011-10-17       Impact factor: 4.157

10.  The effects of maternally administered methadone, buprenorphine and naltrexone on offspring: review of human and animal data.

Authors:  W O Farid; S A Dunlop; R J Tait; G K Hulse
Journal:  Curr Neuropharmacol       Date:  2008-06       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.